MetaCap

Aligos Therapeutics (ALGS) vs Black Hawk Acquisition (BKHA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Black Hawk Acquisition is the larger company by market cap ($7.7 million vs $7.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALGS-77.07%BKHA-85.77%
+8%-41%-90%
Oct 7, 20261 yearNov 20, 2026
ALGS-77.15%BKHA-83.95%
+4%-42%-88%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALGS versus BKHA key metrics
MetricALGSBKHA
Share price$1.22$1.85
Market cap$7.62M$7.68M
1-day change-2.40%-71.45%
YTD return-86.91%—
1-year return-86.75%—
5-year return-99.70%—
P/E ratio (TTM)—5.61
EPS (TTM)$-6.46$0.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.19M—
Revenue growth (YoY)-39.46%—
Net income (latest FY)$-24.19M$1.33M
Operating margin-4024.93%—
Net margin-1106.72%—
52-week high$13.69$23.00
52-week low$1.18$1.75
Distance from 52-week high-91.09%-91.96%
Analyst consensusnone—
Avg. price target upside+4193.44%—
Average volume57.37K101.40K
Shares outstanding5.45M4.15M
Employees82—
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aligos Therapeutics

ALGS stock →

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees

About Black Hawk Acquisition

BKHA stock →

Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

ALGS vs BKHA FAQ

Which is bigger, Aligos Therapeutics or Black Hawk Acquisition?

Black Hawk Acquisition (BKHA) is larger, with a market capitalization of $7.68M compared with $7.62M for Aligos Therapeutics (ALGS).

Are Aligos Therapeutics and Black Hawk Acquisition in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons